中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
23期
37-38,39
,共3页
重组牛碱性成纤维细胞生长因子眼用凝胶%玻璃酸钠滴眼液%睑板腺异常%干眼%临床疗效
重組牛堿性成纖維細胞生長因子眼用凝膠%玻璃痠鈉滴眼液%瞼闆腺異常%榦眼%臨床療效
중조우감성성섬유세포생장인자안용응효%파리산납적안액%검판선이상%간안%림상료효
recombinant bovine basic fibroblast growth factor ophthalmic gel%sodium hyaluronate eye drop%meibomian gland abnormality%dry eye%clinical efficacy
目的：比较重组牛碱性成纤维细胞生长因子眼用凝胶和玻璃酸钠滴眼液对睑板腺异常相关干眼的治疗效果。方法将2012年3月至2013年8月收治的睑板腺异常相关干眼患者73例（73只眼），随机分为重组牛碱性成纤维细胞生长因子眼用凝胶组（观察组）和玻璃酸钠滴眼液组（对照组）。比较两组患者治疗前及治疗后15，30 d 的临床症状评分、泪膜破裂时间（BUT）、泪液分泌试验（Schirmer Ⅰa）、角膜荧光素染色评分（FL）及睑板腺评分，统计治疗总有效率。结果两组治疗后30 d 临床症状评分、BUT 及 FL 评分均优于治疗前及治疗后15 d（均 P <0.05)；治疗后30 d，观察组临床症状评分、BUT 及 FL 评分均优于对照组（均 P <0.05)；两组治疗前后 Schirmer Ⅰa 及睑板腺评分未见改善（均 P >0.05）。观察组治疗总有效率明显高于对照组（ P <0.05）。结论重组牛碱性成纤维细胞生长因子眼用凝胶和玻璃酸钠滴眼液均可改善患者的临床症状，延长泪膜破裂时间，修复角膜损伤，但前者疗效优于后者。两者对睑板腺功能障碍的改善作用均不佳，需配合其他药物治疗。
目的：比較重組牛堿性成纖維細胞生長因子眼用凝膠和玻璃痠鈉滴眼液對瞼闆腺異常相關榦眼的治療效果。方法將2012年3月至2013年8月收治的瞼闆腺異常相關榦眼患者73例（73隻眼），隨機分為重組牛堿性成纖維細胞生長因子眼用凝膠組（觀察組）和玻璃痠鈉滴眼液組（對照組）。比較兩組患者治療前及治療後15，30 d 的臨床癥狀評分、淚膜破裂時間（BUT）、淚液分泌試驗（Schirmer Ⅰa）、角膜熒光素染色評分（FL）及瞼闆腺評分，統計治療總有效率。結果兩組治療後30 d 臨床癥狀評分、BUT 及 FL 評分均優于治療前及治療後15 d（均 P <0.05)；治療後30 d，觀察組臨床癥狀評分、BUT 及 FL 評分均優于對照組（均 P <0.05)；兩組治療前後 Schirmer Ⅰa 及瞼闆腺評分未見改善（均 P >0.05）。觀察組治療總有效率明顯高于對照組（ P <0.05）。結論重組牛堿性成纖維細胞生長因子眼用凝膠和玻璃痠鈉滴眼液均可改善患者的臨床癥狀，延長淚膜破裂時間，脩複角膜損傷，但前者療效優于後者。兩者對瞼闆腺功能障礙的改善作用均不佳，需配閤其他藥物治療。
목적：비교중조우감성성섬유세포생장인자안용응효화파리산납적안액대검판선이상상관간안적치료효과。방법장2012년3월지2013년8월수치적검판선이상상관간안환자73례（73지안），수궤분위중조우감성성섬유세포생장인자안용응효조（관찰조）화파리산납적안액조（대조조）。비교량조환자치료전급치료후15，30 d 적림상증상평분、루막파렬시간（BUT）、루액분비시험（Schirmer Ⅰa）、각막형광소염색평분（FL）급검판선평분，통계치료총유효솔。결과량조치료후30 d 림상증상평분、BUT 급 FL 평분균우우치료전급치료후15 d（균 P <0.05)；치료후30 d，관찰조림상증상평분、BUT 급 FL 평분균우우대조조（균 P <0.05)；량조치료전후 Schirmer Ⅰa 급검판선평분미견개선（균 P >0.05）。관찰조치료총유효솔명현고우대조조（ P <0.05）。결론중조우감성성섬유세포생장인자안용응효화파리산납적안액균가개선환자적림상증상，연장루막파렬시간，수복각막손상，단전자료효우우후자。량자대검판선공능장애적개선작용균불가，수배합기타약물치료。
Objective To investigate the efficacy of Recombinant Bovine Basic Fibroblast growth Factor Ophthalmic gel and Sodium Hyaluronate Eye Drops for the treatment of meibomian gland abnormality related dry eye. Methods 73 patients (73 eyes) with meibo-mian gland abnormaly related dry eye in the department of ophthalmology of our hospital from march 2012 to march 2013 were ran-domly divided into the Recombinant Bovine Basic Fibroblast growth Factor Ophthalmic gel group (observation group) and Sodium Hyaluronate Eye Drops group( control group) . And the clinical symptom score, tear film breakup time ( BUT) , Schirmer test ( Schirmer Ia), corneal fluorescein staining score (FL) and meibomian gland score before treatment and on 15, 30 d after treatment were compared between the two groups. Results The clinical symptom scores, BUT and FL scores after 30 d treatment in the two groups were both better than those before treatment and after 15 d treatment (all P < 0. 05 ); the clinical symptom scores, BUT and FL scores after 30 d treatment in the observation group were better than those in the control group (all P < 0. 05); the Schirmer Ia and the meibomian gland score after treatment in the two groups had no improvement compared with before treatment(all P > 0. 05) . The effective rate of the observation group was higher than that of the control group and the total effect had statistically significant difference between the two groups( P < 0. 05) . Conclusion Recombinant Bovine Basic Fibroblast growth Factor Ophthalmic gel and Sodium Hyaluronate Eye Drops can both improve the clinical symptoms, prolong the tear film BUT and repair corneal damage for treating meibomian gland ab-normality related dry eye, but the former is more effective than the latter. The effects of both two methods for improving the meibomian gland dysfunction are poor, which needs to coordinated with other medication therapy.
